Preliminary Evidence of Efficacy for Policol<sup>®</sup> One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU

Llabrés Josep Manuel; Mu&ntilde;oz Pastor Nuria

doi:doi:10.11648/j.wjfst.20220601.11

| Peer-Reviewed

Preliminary Evidence of Efficacy for Policol^® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU

Llabrés Josep Manuel, Muñoz Pastor Nuria

Published in World Journal of Food Science and Technology (Volume 6, Issue 1)

Received: 18 January 2022 Accepted: 9 February 2022 Published: 25 February 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Cholesterol is necessary for many cell functions but it can also be harmful if it is allowed to reach high blood concentrations, as the risk for premature atherosclerotic cardiovascular diseases increases. Many food supplements contain currently 10 mg of monacolin K in order to benefit of the approved claim to maintain normal blood LDL-cholesterol levels. However, the EFSA has considered that cases of adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. That is the reason why the main aim of the present study was to show the effect of Policol^® One new formula in patients with non-desirable lipidic profile levels. Policol^® One new formula contains a wide range of plant extracts with not only a traditional use, but also a proven effect on plasma lipids. The consumption of one capsule of new Policol^® One during dinner for only 4 weeks favorably affected plasma LDL-C (-39.52%) and TC (-40.52%) levels in healthy volunteers. No significant effect on TG and HDL-C was shown after 4 weeks. However, after 12 weeks TG biomarker exhibited a significant reduction (-19.91%) and HDL-C (+9.84%) also improved. No adverse effects were reported during the study. Lower lipid properties may be associated with a synergistic effect of the ingredients which allow us to formulate with a lower and safer dosage of monacolin K.

Published in	World Journal of Food Science and Technology (Volume 6, Issue 1)
DOI	10.11648/j.wjfst.20220601.11
Page(s)	1-9
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Monascus Purpureus, Policosanol, Guggul, Cholesterol, Natural Therapies, Policol^® One

References

[1]	Huff T, Boyd B, Jialal I. Physiology, Cholesterol. StatPearls, Treasure Island (FL): StatPearls Publishing; 2021.
[2]	Burger K, Gimpl G, Fahrenholz F. Regulation of receptor function by cholesterol: CMLS, Cell Mol Life Sci 2000; 57: 1577–92. https://doi.org/10.1007/PL00000643.
[3]	Lecerf J-M, de Lorgeril M. Dietary cholesterol: from physiology to cardiovascular risk. Br J Nutr 2011; 106: 6–14. https://doi.org/10.1017/S0007114511000237.
[4]	Indicator Metadata Registry Details n.d. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3236 (accessed December 10, 2021).
[5]	Ministerio de Sanidad, Consumo y Bienestar Social - Portal Estadístico del SNS - Encuesta Nacional de Salud de España 2017 n.d. https://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/encuesta2017.htm (accessed December 10, 2021).
[6]	Guías de Buena Práctica Clínica \| CGCOM n.d. https://www.cgcom.es/guias_practica_clinica (accessed December 10, 2021).
[7]	Guía ESC/EAS 2019 sobre el tratamiento de las dislipemias: modificación de los lípidos para reducir el riesgo cardiovascular. Revista Española de Cardiología 2020; 73: 403. e1-403. e70. https://doi.org/10.1016/j.recesp.2019.10.031.
[8]	Sirtori CR. The pharmacology of statins. Pharmacological Research 2014; 88: 3–11. https://doi.org/10.1016/j.phrs.2014.03.002.
[9]	Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, et al. The role of nutraceuticals in statin intolerant patients. Journal of the American College of Cardiology 2018; 72: 96–118. https://doi.org/10.1016/j.jacc.2018.04.040.
[10]	Llabrés JM, Urcola I, Boada JM, Araujo JC, Durán J. Estudio piloto sobre el efecto de Policol One en la hipercolesterolemia leve moderada. Revista Fitoterapia 2017 n.d.; 17 (1): 63–70.
[11]	EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA J 2011; 9: 2304.
[12]	Heinz T, Schuchardt JP, Möller K, Hadji P, Hahn A. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. Nutrition Research 2016; 36: 1162–70. https://doi.org/10.1016/j.nutres.2016.07.005.
[13]	Poli A, Visioli F. Pharmacology of nutraceuticals with lipid lowering properties. High Blood Press Cardiovasc Prev 2019; 26: 113–8. https://doi.org/10.1007/s40292-019-00311-x.
[14]	Santini A, Novellino E. Nutraceuticals in hypercholesterolaemia: an overview: nutraceuticals and hypercholesterolaemia. British Journal of Pharmacology 2017; 174: 1450–63. https://doi.org/10.1111/bph.13636.
[15]	Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Aoms 2017; 5: 965–1005. https://doi.org/10.5114/aoms.2017.69326.
[16]	Elwood JC, Nash DT, Streeten DH. Effect of high-chromium brewer’s yeast on human serum lipids. Journal of the American College of Nutrition 1982; 1: 263–74. https://doi.org/10.1080/07315724.1982.10718995.
[17]	Khosravi-Boroujeni H, Rostami A, Ravanshad S, Esmaillzadeh A. Favorable effects on metabolic risk factors with daily brewer’s yeast in type 2 diabetic patients with hypercholesterolemia: A semi-experimental study: Brewer’s yeast in patients with T2DM. Journal of Diabetes 2012; 4: 153–8. https://doi.org/10.1111/j.1753-0407.2011.00163.x.
[18]	Suárez-Rivero JM, Pastor-Maldonado CJ, de la Mata M, Villanueva-Paz M, Povea-Cabello S, Álvarez-Córdoba M, et al. Atherosclerosis and coenzyme Q10. IJMS 2019; 20: 5195. https://doi.org/10.3390/ijms20205195.
[19]	Qu H, Guo M, Chai H, Wang W, Gao Z, Shi D. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. JAHA 2018; 7. https://doi.org/10.1161/JAHA.118.009835.
[20]	Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). The Journal of Nutritional Biochemistry 2003; 14: 298–305. https://doi.org/10.1016/S0955-2863(02)00284-X.
[21]	Deng R. Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev 2007; 25: 375–90. https://doi.org/10.1111/j.1527-3466.2007.00023.x.
[22]	Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drug Ther 1994; 8: 659–64. https://doi.org/10.1007/BF00877420.
[23]	Porcel Vaca KM, Cuellar Aguilera JD. Efectividad del licuado de alpiste como tratamiento reductor del colesterol, triglicéridos y el índice de masa corporal. UCEBOL 2010: 7–12.
[24]	Policosanol (Saccharum Officinarum L.) Benefits and uses including lowering cholesterol n.d. https://altmedrev.com/blog/resource/policosanol/ (accessed December 10, 2021).
[25]	Alcachofera \| fitoterapia.net n.d. https://www.fitoterapia.net/vademecum/plantas/alcachofera.html (accessed July 29, 2021).
[26]	WHO monographs on selected medicinal plants. vol. 3. 2007.
[27]	Schütz K, Carle R, Schieber A. Taraxacum—A review on its phytochemical and pharmacological profile. Journal of Ethnopharmacology 2006; 107: 313–23. https://doi.org/10.1016/j.jep.2006.07.021.
[28]	Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Alternative Lipid Lowering in Patients With Statin Intolerance: Use of Red Yeast Rice and Therapeutic Lifestyle Changes in a Randomized, Placebo-Controlled Trial. Chestnut Hill Health System; 2007.
[29]	Coca A, Cea-Calvo L, Lozano JV, Inaraja V, Fernández-Pérez C, Navarro J, et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease in Spanish Hypertensive Women. The RIMHA Study. Revista Española de Cardiología (English Edition) 2009; 62: 1022–31. https://doi.org/10.1016/S1885-5857(09)73268-2.
[30]	Alfonso JEF, Ariza IDS. Elevando el colesterol HDL: Cuál es la mejor estrategia? Rev Assoc Med Bras 2008; 54: 369–76. https://doi.org/10.1590/S0104-42302008000400025.

Cite This Article

Plain Text BibTeX RIS

APA Style

Llabrés Josep Manuel, Muñoz Pastor Nuria. (2022). Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World Journal of Food Science and Technology, 6(1), 1-9. https://doi.org/10.11648/j.wjfst.20220601.11

Copy | Download

ACS Style

Llabrés Josep Manuel; Muñoz Pastor Nuria. Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World J. Food Sci. Technol. 2022, 6(1), 1-9. doi: 10.11648/j.wjfst.20220601.11

Copy | Download

AMA Style

Llabrés Josep Manuel, Muñoz Pastor Nuria. Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World J Food Sci Technol. 2022;6(1):1-9. doi: 10.11648/j.wjfst.20220601.11

Copy | Download

@article{10.11648/j.wjfst.20220601.11,
  author = {Llabrés Josep Manuel and Muñoz Pastor Nuria},
  title = {Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU},
  journal = {World Journal of Food Science and Technology},
  volume = {6},
  number = {1},
  pages = {1-9},
  doi = {10.11648/j.wjfst.20220601.11},
  url = {https://doi.org/10.11648/j.wjfst.20220601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjfst.20220601.11},
  abstract = {Cholesterol is necessary for many cell functions but it can also be harmful if it is allowed to reach high blood concentrations, as the risk for premature atherosclerotic cardiovascular diseases increases. Many food supplements contain currently 10 mg of monacolin K in order to benefit of the approved claim to maintain normal blood LDL-cholesterol levels. However, the EFSA has considered that cases of adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. That is the reason why the main aim of the present study was to show the effect of Policol® One new formula in patients with non-desirable lipidic profile levels. Policol® One new formula contains a wide range of plant extracts with not only a traditional use, but also a proven effect on plasma lipids. The consumption of one capsule of new Policol® One during dinner for only 4 weeks favorably affected plasma LDL-C (-39.52%) and TC (-40.52%) levels in healthy volunteers. No significant effect on TG and HDL-C was shown after 4 weeks. However, after 12 weeks TG biomarker exhibited a significant reduction (-19.91%) and HDL-C (+9.84%) also improved. No adverse effects were reported during the study. Lower lipid properties may be associated with a synergistic effect of the ingredients which allow us to formulate with a lower and safer dosage of monacolin K.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU
AU  - Llabrés Josep Manuel
AU  - Muñoz Pastor Nuria
Y1  - 2022/02/25
PY  - 2022
N1  - https://doi.org/10.11648/j.wjfst.20220601.11
DO  - 10.11648/j.wjfst.20220601.11
T2  - World Journal of Food Science and Technology
JF  - World Journal of Food Science and Technology
JO  - World Journal of Food Science and Technology
SP  - 1
EP  - 9
PB  - Science Publishing Group
SN  - 2637-6024
UR  - https://doi.org/10.11648/j.wjfst.20220601.11
AB  - Cholesterol is necessary for many cell functions but it can also be harmful if it is allowed to reach high blood concentrations, as the risk for premature atherosclerotic cardiovascular diseases increases. Many food supplements contain currently 10 mg of monacolin K in order to benefit of the approved claim to maintain normal blood LDL-cholesterol levels. However, the EFSA has considered that cases of adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. That is the reason why the main aim of the present study was to show the effect of Policol® One new formula in patients with non-desirable lipidic profile levels. Policol® One new formula contains a wide range of plant extracts with not only a traditional use, but also a proven effect on plasma lipids. The consumption of one capsule of new Policol® One during dinner for only 4 weeks favorably affected plasma LDL-C (-39.52%) and TC (-40.52%) levels in healthy volunteers. No significant effect on TG and HDL-C was shown after 4 weeks. However, after 12 weeks TG biomarker exhibited a significant reduction (-19.91%) and HDL-C (+9.84%) also improved. No adverse effects were reported during the study. Lower lipid properties may be associated with a synergistic effect of the ingredients which allow us to formulate with a lower and safer dosage of monacolin K.
VL  - 6
IS  - 1
ER  -

Copy | Download

Author Information

Llabrés Josep Manuel

Research and Development Department, Plameca S.A, Barcelona, Spain
Muñoz Pastor Nuria

Research and Development Department, Plameca S.A, Barcelona, Spain

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Llabrés Josep Manuel, Muñoz Pastor Nuria. (2022). Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World Journal of Food Science and Technology, 6(1), 1-9. https://doi.org/10.11648/j.wjfst.20220601.11

Copy | Download

ACS Style

Llabrés Josep Manuel; Muñoz Pastor Nuria. Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World J. Food Sci. Technol. 2022, 6(1), 1-9. doi: 10.11648/j.wjfst.20220601.11

Copy | Download

AMA Style

Llabrés Josep Manuel, Muñoz Pastor Nuria. Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU. World J Food Sci Technol. 2022;6(1):1-9. doi: 10.11648/j.wjfst.20220601.11

Copy | Download

@article{10.11648/j.wjfst.20220601.11,
  author = {Llabrés Josep Manuel and Muñoz Pastor Nuria},
  title = {Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU},
  journal = {World Journal of Food Science and Technology},
  volume = {6},
  number = {1},
  pages = {1-9},
  doi = {10.11648/j.wjfst.20220601.11},
  url = {https://doi.org/10.11648/j.wjfst.20220601.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjfst.20220601.11},
  abstract = {Cholesterol is necessary for many cell functions but it can also be harmful if it is allowed to reach high blood concentrations, as the risk for premature atherosclerotic cardiovascular diseases increases. Many food supplements contain currently 10 mg of monacolin K in order to benefit of the approved claim to maintain normal blood LDL-cholesterol levels. However, the EFSA has considered that cases of adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. That is the reason why the main aim of the present study was to show the effect of Policol® One new formula in patients with non-desirable lipidic profile levels. Policol® One new formula contains a wide range of plant extracts with not only a traditional use, but also a proven effect on plasma lipids. The consumption of one capsule of new Policol® One during dinner for only 4 weeks favorably affected plasma LDL-C (-39.52%) and TC (-40.52%) levels in healthy volunteers. No significant effect on TG and HDL-C was shown after 4 weeks. However, after 12 weeks TG biomarker exhibited a significant reduction (-19.91%) and HDL-C (+9.84%) also improved. No adverse effects were reported during the study. Lower lipid properties may be associated with a synergistic effect of the ingredients which allow us to formulate with a lower and safer dosage of monacolin K.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Preliminary Evidence of Efficacy for Policol® One Cholesterol Lowering Effect from Week 4, Adapted to the Upcoming Restrictions for Monacolins in Food in the EU
AU  - Llabrés Josep Manuel
AU  - Muñoz Pastor Nuria
Y1  - 2022/02/25
PY  - 2022
N1  - https://doi.org/10.11648/j.wjfst.20220601.11
DO  - 10.11648/j.wjfst.20220601.11
T2  - World Journal of Food Science and Technology
JF  - World Journal of Food Science and Technology
JO  - World Journal of Food Science and Technology
SP  - 1
EP  - 9
PB  - Science Publishing Group
SN  - 2637-6024
UR  - https://doi.org/10.11648/j.wjfst.20220601.11
AB  - Cholesterol is necessary for many cell functions but it can also be harmful if it is allowed to reach high blood concentrations, as the risk for premature atherosclerotic cardiovascular diseases increases. Many food supplements contain currently 10 mg of monacolin K in order to benefit of the approved claim to maintain normal blood LDL-cholesterol levels. However, the EFSA has considered that cases of adverse reactions have been reported for monacolins from red yeast rice at intake levels as low as 3 mg/day. That is the reason why the main aim of the present study was to show the effect of Policol® One new formula in patients with non-desirable lipidic profile levels. Policol® One new formula contains a wide range of plant extracts with not only a traditional use, but also a proven effect on plasma lipids. The consumption of one capsule of new Policol® One during dinner for only 4 weeks favorably affected plasma LDL-C (-39.52%) and TC (-40.52%) levels in healthy volunteers. No significant effect on TG and HDL-C was shown after 4 weeks. However, after 12 weeks TG biomarker exhibited a significant reduction (-19.91%) and HDL-C (+9.84%) also improved. No adverse effects were reported during the study. Lower lipid properties may be associated with a synergistic effect of the ingredients which allow us to formulate with a lower and safer dosage of monacolin K.
VL  - 6
IS  - 1
ER  -

Copy | Download